Exelixis Inc (EXEL : NASDAQ)
Common Stock
$66.28
USD
+0.93 (1.42%)
Last updated: 2026-10-28
Follow EXEL
EXEL
Exelixis Inc
WealthAwesomePerformance
1 Day
+1.42%
1 Week
+2.63%
1 Month
+13.55%
YTD
+26.39%
Key Statistics
Market Cap
$16.42B
52W High
$66.38
52W Low
$36.00
P/E Ratio
20.58
50 Day MA
$58.57
200 Day MA
$50.57
Beta
0.47
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/28/2026 | $64.90 | $66.38 | $64.75 | $66.28 | $66.28 | 1,639,518 |
| 10/27/2026 | $64.70 | $65.48 | $64.39 | $65.35 | $65.35 | 1,431,200 |
| 10/26/2026 | $64.85 | $65.58 | $64.57 | $65.11 | $65.11 | 1,674,578 |
| 10/23/2026 | $65.15 | $65.20 | $63.91 | $64.53 | $64.53 | 2,066,200 |
| 10/22/2026 | $64.74 | $65.50 | $64.33 | $65.31 | $65.31 | 1,708,906 |
| 10/21/2026 | $64.12 | $64.78 | $64.11 | $64.58 | $64.58 | 1,494,211 |
| 10/20/2026 | $63.01 | $64.42 | $62.84 | $64.39 | $64.39 | 2,135,578 |
| 10/19/2026 | $61.84 | $62.81 | $61.67 | $62.68 | $62.68 | 1,933,117 |
| 10/16/2026 | $62.98 | $63.39 | $61.74 | $62.23 | $62.23 | 2,637,300 |
| 10/15/2026 | $61.69 | $63.31 | $61.28 | $62.83 | $62.83 | 2,773,800 |
Analyst Price Targets
Based on 18 analysts covering EXEL · as of Oct 20, 2026
Wall Street analysts forecast EXEL stock price to fall 16.2% over the next 12 months.
Consensus
Buy3.67 / 5.00
Avg. Target
US$55.53
-16.2% Upside
Previously US$54.87 on Oct 12, 2026
Current Price
US$66.28
Last close
Analyst Breakdown (18 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EXEL's historical volatility
30-Day Vol
21.6%
Annualized
90-Day Vol
31.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$79.24
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$70.35 | US$65.28 – US$75.80 |
| 60 trading days | US$74.66 | US$67.18 – US$82.97 |
| 90 trading days | US$79.24 | US$69.63 – US$90.18 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Exelixis Inc
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Financials
- Revenue (TTM)
- $2.44B
- EBITDA
- $1.02B
- Profit Margin
- 35.33%
- ROE (TTM)
- 44.39%
- EPS (Diluted)
- 3.22
- Book Value
- 7.41
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About EXEL.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| AXG | Solowin Holdings | $5.68 | +14100.00% |
| ATYR | aTyr Pharma, Inc. | $5.14 | +4041.94% |
| OMEX | Odyssey Marine Exploration Inc | $13.55 | +2418.59% |
| HVII | Hennessy Capital Investment Corp. VII Ordinary Shares | $4.46 | +243.08% |
| ULBI | Ultralife Corporation | $15.61 | +145.44% |
| ATII | Archimedes Tech SPAC Partners II Co. Ordinary Shares | $9.81 | +110.06% |
| RITRF | Reitar Logtech Holdings Limited | $0.02 | +86.09% |
| KPTI | Karyopharm Therapeutics Inc | $0.83 | +73.35% |
EXEL.US news timeline
1 article covering EXEL.US, most recent first
Latest